REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.62
+0.21 (2.83%)
At close: Dec 20, 2024, 4:00 PM
7.71
+0.09 (1.18%)
After-hours: Dec 20, 2024, 7:01 PM EST
REGENXBIO Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 36, with a low estimate of 18 and a high estimate of 52. The average target predicts an increase of 372.44% from the current stock price of 7.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 5 | 6 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +359.32% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $36 | Strong Buy | Maintains | $40 → $36 | +372.44% | Nov 21, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +582.41% | Nov 20, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $22 | Buy | Initiates | $22 | +188.71% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +424.93% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
92.35M
from 90.24M
Increased by 2.34%
Revenue Next Year
317.39M
from 92.35M
Increased by 243.67%
EPS This Year
-4.89
from -6.02
EPS Next Year
-0.88
from -4.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 135.5M | 490.0M | 325.1M | |||
| Avg | 92.4M | 317.4M | 193.2M | |||
| Low | 75.6M | 195.0M | 103.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 50.1% | 430.6% | 2.4% | |||
| Avg | 2.3% | 243.7% | -39.1% | |||
| Low | -16.3% | 111.2% | -67.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.23 | 1.94 | -2.77 | |||
| Avg | -4.89 | -0.88 | -3.71 | |||
| Low | -5.36 | -3.07 | -5.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.